Advisory Alpha LLC Has $1.34 Million Position in Stryker Corporation $SYK

Advisory Alpha LLC increased its position in Stryker Corporation (NYSE:SYK) by 4.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 3,391 shares of the medical technology company’s stock after acquiring an additional 151 shares during the period. Advisory Alpha LLC’s holdings in Stryker were worth $1,342,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in SYK. Brighton Jones LLC increased its holdings in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Golden State Wealth Management LLC grew its holdings in Stryker by 24.1% during the first quarter. Golden State Wealth Management LLC now owns 247 shares of the medical technology company’s stock valued at $92,000 after purchasing an additional 48 shares during the last quarter. Valley National Advisers Inc. raised its position in shares of Stryker by 68.6% in the first quarter. Valley National Advisers Inc. now owns 263 shares of the medical technology company’s stock valued at $98,000 after purchasing an additional 107 shares during the period. Red Door Wealth Management LLC raised its position in shares of Stryker by 6.9% in the first quarter. Red Door Wealth Management LLC now owns 779 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 50 shares during the period. Finally, Smallwood Wealth Investment Management LLC bought a new position in shares of Stryker in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 5.20% of the company’s stock.

Stryker Trading Down 2.0%

Shares of Stryker stock opened at $376.11 on Wednesday. The company’s fifty day simple moving average is $379.59 and its 200-day simple moving average is $380.49. The company has a market cap of $143.79 billion, a price-to-earnings ratio of 49.82, a PEG ratio of 2.76 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. Stryker’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on SYK shares. Truist Financial dropped their price target on shares of Stryker from $415.00 to $407.00 and set a “hold” rating on the stock in a research report on Wednesday, October 15th. Evercore ISI dropped their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 7th. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Wall Street Zen raised shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Wells Fargo & Company lifted their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $432.24.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.